466 related articles for article (PubMed ID: 16624928)
21. MPO-ANCA-associated pulmonary-renal vasculitis in a patient with diabetes mellitus.
Keven K; Akar H; Kutlay S; Nergizoglu G; Erbay B; Erturk S
J Nephrol; 2002; 15(6):720-3. PubMed ID: 12495292
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies.
Schreiber A; Xiao H; Falk RJ; Jennette JC
J Am Soc Nephrol; 2006 Dec; 17(12):3355-64. PubMed ID: 17108314
[TBL] [Abstract][Full Text] [Related]
23. [Rapidly progressive ANCA-negative glomerulonephritis in the course of pauci immune microscopic vasculitis with hemolytic anemia probable in the course of Wilson's disease].
Wieczorek-Surdacka E; Kaczmarczyk I; Jasik P; Przepiórkowska-Hoyer B; Sułowicz W
Przegl Lek; 2011; 68(2):123-5. PubMed ID: 21751523
[TBL] [Abstract][Full Text] [Related]
24. Role of antineutrophil cytoplasmic antibodies and glomerular basement membrane antibodies in the diagnosis and monitoring of systemic vasculitides.
Sinclair D; Stevens JM
Ann Clin Biochem; 2007 Sep; 44(Pt 5):432-42. PubMed ID: 17761028
[TBL] [Abstract][Full Text] [Related]
25. Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils.
Hu N; Westra J; Huitema MG; Bijl M; Brouwer E; Stegeman CA; Heeringa P; Limburg PC; Kallenberg CG
Arthritis Rheum; 2009 May; 60(5):1548-57. PubMed ID: 19404956
[TBL] [Abstract][Full Text] [Related]
26. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic?
Tervaert JW; Heeringa P
Neth J Med; 2003 Dec; 61(12):404-7. PubMed ID: 15025415
[TBL] [Abstract][Full Text] [Related]
27. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
[TBL] [Abstract][Full Text] [Related]
28. Treatment of ANCA-associated systemic vasculitis.
Belmont HM
Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492
[TBL] [Abstract][Full Text] [Related]
29. Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies.
Brachemi S; Mambole A; Fakhouri F; Mouthon L; Guillevin L; Lesavre P; Halbwachs-Mecarelli L
J Am Soc Nephrol; 2007 Aug; 18(8):2330-9. PubMed ID: 17634439
[TBL] [Abstract][Full Text] [Related]
30. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin.
Jayne DR; Esnault VL; Lockwood CM
J Autoimmun; 1993 Apr; 6(2):207-19. PubMed ID: 8499059
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
[TBL] [Abstract][Full Text] [Related]
32. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases.
Lamprecht P
Autoimmun Rev; 2005 Jan; 4(1):28-34. PubMed ID: 15652776
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of PR3-ANCA associated vasculitis.
Kallenberg CG
J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
[TBL] [Abstract][Full Text] [Related]
34. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation.
Vielhauer V; Mayadas TN
Semin Nephrol; 2007 May; 27(3):286-308. PubMed ID: 17533007
[TBL] [Abstract][Full Text] [Related]
35. Anti-endothelial cell antibodies in antineutrophil cytoplasmic antibodies negative pauci-immune crescentic glomerulonephritis.
Cong M; Chen M; Zhang JJ; Hu Z; Zhao MH
Nephrology (Carlton); 2008 Jun; 13(3):228-34. PubMed ID: 18315705
[TBL] [Abstract][Full Text] [Related]
36. Treatment with cytapheresis for antineutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-inflammatory factors.
Hasegawa M; Watanabe A; Takahashi H; Takahashi K; Kasugai M; Kawamura N; Kushimoto H; Murakami K; Tomita M; Nabeshima K; Oohashi A; Kondou F; Ooshima H; Hiki Y; Sugiyama S
Ther Apher Dial; 2005 Aug; 9(4):297-302. PubMed ID: 16076370
[TBL] [Abstract][Full Text] [Related]
37. Targeting B lymphocytes as therapy for ANCA-associated vasculitis.
Golbin JM; Specks U
Rheum Dis Clin North Am; 2007 Nov; 33(4):741-54, v. PubMed ID: 18037114
[TBL] [Abstract][Full Text] [Related]
38. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
Holle JU; Gross WL
J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
[TBL] [Abstract][Full Text] [Related]
39. D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.
Bienaimé F; Clerbaux G; Plaisier E; Mougenot B; Ronco P; Rougier JP
Am J Kidney Dis; 2007 Nov; 50(5):821-5. PubMed ID: 17954295
[TBL] [Abstract][Full Text] [Related]
40. Improvements in treatment strategies for patients with antineutrophil cytoplasmic antibody-associated rapidly progressive glomerulonephritis.
Hotta O; Ishida A; Kimura T; Taguma Y
Ther Apher Dial; 2006 Oct; 10(5):390-5. PubMed ID: 17096692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
